Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Stakeholder Opinions: Type 2 Diabetes in the UAE & Saudi Arabia Growth opportunities in fragmented markets

Published by: Datamonitor

Published: Dec. 19, 2008 - 27 Pages


Table of Contents


ABOUT DATAMONITOR HEALTHCARE
About the Cardiovascular pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
Scope of the analysis
Datamonitor insight into type 2 diabetes in the UAE and Saudi Arabia
Related reports
Upcoming reports
Key Opinion Leaders Interviewed
CHAPTER 2 DEFINITION OF DIABETES AND DISEASE OVERVIEW
Definition of diabetes
Segmentation of diabetes
Type 1 diabetes
Type 2 diabetes
Etiology of diabetes
Mechanisms of development of diabetes
Genetic or acquired causes
Risk factors
Obesity
The type 2 diabetes epidemic goes hand-in-hand with the obesity epidemic.
Family history
Type 2 diabetes in first-degree relatives is a strong prognostic indicator
Advanced age
Diagnosis of type 2 diabetes may be overlooked in older patients
Gender
Risk of type 2 diabetes may be greater in females
History of prediabetes
Physical inactivity
Diet and western lifestyle
Arab and South Asian genetic susceptibility
Consanguinity and thalassemia minor are risk factors for diabetes.
Other factors
Socio-economic traditions
The role of alcohol and fasting blood glucose
Vitamin D deficiency and diabetes
Epidemiology
Increasing prevalence of diabetes in the GCC
Economic burden of diabetes
CHAPTER 3 DIAGNOSIS OF TYPE 2 DIABETES
Diagnosis of type 2 diabetes
Patient management
Management of diabetes should be done by a team, not just a specialist
Healthcare provision in Saudi Arabia is highly fragmented
Abu Dhabi and Dubai have excellent healthcare facilities, but the northern emirates are lagging behind.
Abu Dhabi
Dubai
The role of PCPs in type 2 diabetes management
Referral to specialist
Reasons for poor diagnosis
Insidious nature of the disease
Lack of screening
Awareness of guidelines
Strategies to increase diagnosis rates
Improving guideline awareness of PCPs
There is a need for a targeted screening program
Strategies to prevent diabetes
Preemptive treatment
Education in the UAE
Building awareness of diabetes in Saudi Arabia
CHAPTER 4 DIABETIC COMPLICATIONS
Complications of diabetes
Nephropathy
Effect of nephropathy on type 2 diabetes treatment
Retinopathy
Effect of retinopathy on type 2 diabetes treatment
Neuropathy
Effect of neuropathy on type 2 diabetes treatment
Macrovascular complications
Effect of macrovascular complications on type 2 diabetes treatment
Co-morbidities
Obesity
Effect of obesity on type 2 diabetes treatment
Hypertension
Dyslipidemia
CHAPTER 5 CURRENT TREATMENT OPTIONS FOR TYPE 2 DIABETES
International treatment guidelines for type 2 diabetes
Clinical practice guidelines from the ADA/EASD
The AACE-ACE clinical practice guidelines
Guideline use in the UAE and Saudi Arabia
Treatment patterns
Lifestyle management for type 2 diabetes
Pharmacological treatment
In Saudi Arabia, the new classes of antidiabetics are not yet approved and most branded drugs are not available in MOH primary care centers
KOLs in the UAE are very satisfied with the pharmacological options available for use
Insulin use in Saudi Arabia is limited by the types available to physicians
Alternative and adjunct therapies
Prescribing trends and influences
Slow approvals by the SFDA and the exlusion of drugs from MOH formularies hampers prescription in Saudi Arabia, while the latest drugs are available to physicians in the UAE.
Nationality influences the standard of care available
Self-management
CHAPTER 6 UNMET NEEDS
Limited availability of drugs
The need to build awareness of diabetes, obesity and healthy lifestyle
The need for diabetes education teams
Guideline awareness of PCPs
Patient compliance
CHAPTER 7 COMMERCIAL IMPLICATIONS OF FINDINGS AND RECOMMENDATIONS
GCC is a strategic growth region
Growth through partnerships with regional players
Dubai has created a favorable landscape for foreign healthcare investment
The antidiabetic markets in the UAE and Saudi Arabia are unique
The UAE is very receptive to new antidiabetic drugs and is brand-conscious
The Saudi Arabian market is plagued by slow approvals
Treatment paradigms are highly diverse in the UAE and Saudi Arabia
Use of different guidelines and poor adherence to them
Lack of access to newer antidiabetic therapies in Saudi Arabia
Insufficient insurance coverage impedes delivery of optimal treatment in the UAE
Domestic pharmaceutical sectors
The local pharmaceutical firms in UAE and Saudi Arabia are export-oriented
UAE
Saudi Arabia
Regulatory environments
The privatization of payment will favor generics in the long term
Slow approval procedures in Saudi Arabia
Guideline development is critical in both countries
Recommendations for local and regional generics pharmaceuticals
Recommendations for multinational pharmaceutical companies
Recommendations for healthcare regulators
APPENDIX
About Datamonitor
About Datamonitor Healthcare
About the Disease analysis team
Disclaimer
List of Tables
Table 1: Summary of differences between type 1 and type 2 diabetes
Table 2: Current prevalence of type 2 diabetes, GCC
Table 3: ADA evidence grading system for clinical practice guidelines
Table 4: AACE recommendations for type 2 diabetes patients naïve to pharmacotherapy
Table 5: AACE recommendations for type 2 diabetes patients currently on pharmacotherapy
List of Figures
Figure 1: Percentage of overweight adults aged 15 and over, GCC
Figure 2: Top 10 countries in prevalence of diabetes (20-79 age group)
Figure 3: Current prevalence of diabetes and forecasts for 2025
Figure 4: Treatment algorithm for type 2 diabetes, recommended by the 2006 ADA/EASD clinical practice guidelines
Figure 5: The proportion of diabetics in each GCC country
Figure 6: Population pyramid for Saudi Arabia: 2010
Figure 7: Population pyramid for Saudi Arabia: 2020
Figure 8: Population pyramid for UAE: 2010
Figure 9: Population pyramid for UAE: 2020
Figure 10: UAE pharmaceutical sector sales segmentation
Figure 11: Saudi pharmaceutical sales segmentation

Abstract

Introduction

This report focuses on the challenges of diverse and uncoordinated treatment paradigms for diabetes and the movement to rationalize efforts and establish best practice. Datamonitor uncovers the unique dynamics of the two largest diabetes markets in the GCC; including the impact of regulatory processes such as the healthcare reforms currently being undertaken.

Scope
  • Description and analysis of the uniqueness of the antidiabetic markets in the UAE and Saudi Arabia
  • Fragmented healthcare delivery in the UAE and Saudi Arabia presents opportunity for ramping up sales of generics and novel antidiabetic therapeutics.
  • Commercial implications of Datamonitor's extensive findings and our recommendations to maximize sales in these two markets.
Highlights

Diabetes has reached near-epidemic proportions in the UAE and Saudi Arabia, with nearly one out of every five individuals suffering from diabetes in the UAE. In Saudi Arabia, the prevalence is expected to rise to between 40-50% by 2020.

The delivery of treatment for diabetes is highly fragmented, and leads to sub-optimal treatment for patients in the two countries. The fragmentation is caused by a wide variety of issues due to systemic deficiencies, regulatory changes and socio-economic factors.

Datamonitor has explained the commercial implications of its findings and developed recommendations for healthcare firms and regulators to address the many unmet needs in the treatment of diabetes and to ramp up sales and share of market in both UAE and Saudi Arabia.

Reasons to Purchase
  • Gain an in-depth understanding of the two largest diabetes markets in the GCC; a strategic growth area for healthcare firms.
  • Increase share of the market by effectively targeting the different segments of the population and demands; branded or generic antidiabetic agents.
  • Maximize current and future revenue streams by targeting the numerous growth opportunities identified by Datamonitor.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009